Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS. Requena G, et al. Among authors: ismaila as. Int J Chron Obstruct Pulmon Dis. 2023 Mar 5;18:231-245. doi: 10.2147/COPD.S389281. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 36908830 Free PMC article.
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS. Requena G, et al. Among authors: ismaila as. Int J Chron Obstruct Pulmon Dis. 2023 Jul 13;18:1431-1444. doi: 10.2147/COPD.S411437. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37465818 Free PMC article.
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS. Czira A, et al. Among authors: ismaila as. Int J Chron Obstruct Pulmon Dis. 2023 Apr 19;18:643-659. doi: 10.2147/COPD.S405498. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37155496 Free PMC article.
Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Singh D, Litewka D, Páramo R, Rendon A, Sayiner A, Tanni SE, Acharya S, Aggarwal B, Ismaila AS, Sharma R, Daley-Yates P. Singh D, et al. Among authors: ismaila as. Adv Ther. 2023 Oct;40(10):4689-4690. doi: 10.1007/s12325-023-02613-y. Epub 2023 Jul 28. Adv Ther. 2023. PMID: 37505374 Free PMC article. No abstract available.
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1. Adv Ther. 2023. PMID: 37004642 Free PMC article. No abstract available.
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.
Czira A, Akiyama S, Ishii T, Wood RP, Camidge LJ, Wallis H, Jennison T, Wild RAC, Yarita M, Hashimoto K, Rothnie KJ, Ismaila AS. Czira A, et al. Among authors: ismaila as. Int J Chron Obstruct Pulmon Dis. 2023 Dec 8;18:2933-2953. doi: 10.2147/COPD.S419119. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 38089540 Free PMC article.
Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review.
Czira A, Purushotham S, Iheanacho I, Rothnie KJ, Compton C, Ismaila AS. Czira A, et al. Among authors: ismaila as. Int J Chron Obstruct Pulmon Dis. 2023 Apr 29;18:719-731. doi: 10.2147/COPD.S394325. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37151760 Free PMC article. Review.
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study.
Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R, Compton C, Ismaila A. Czira A, et al. BMJ Open. 2024 Feb 7;14(2):e072361. doi: 10.1136/bmjopen-2023-072361. BMJ Open. 2024. PMID: 38326272 Free PMC article.
96 results